Jax DiEugenio

Dr Mayer on Efficacy Findings With Giredestrant Plus Everolimus in ER+/HER2– Advanced Breast Cancer

December 12th 2025

Erica Mayer, MD, MPH, discusses giredestrant plus everolimus vs physician’s choice of endocrine therapy plus everolimus in ER+, HER2-negative locally advanced or metastatic breast cancer.

Dr Yap on Saruparib/Camizestrant in Advanced ER+, HER2-Negative or HER2-Low Breast Cancer

December 12th 2025

Dr Rugo on Elacestrant-Based Combos in ER+/HER2– Locally Advanced or Metastatic Breast Cancer

December 11th 2025

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.

Dr Alkassis on Cathepsin Protease Expression and Its OS Association With T-DXd in Metastatic Breast Cancer

December 11th 2025

Samer Alkassis, MD, PhD, discusses how cathepsin protease expression may correlate with survival outcomes to trastuzumab deruxtecan in metastatic breast cancer.

Dr Hamilton on First-Line Tucatinib-Based Maintenance in HER2+ Metastatic Breast Cancer

December 10th 2025

Erika P. Hamilton, MD, discusses data from HER2CLIMB-05 evaluating tucatinib plus trastuzumab/pertuzumab first-line maintenance in HER2-positive breast cancer.

Dr Tolaney on Implications of Data for Sacituzumab Govitecan in First-line Advanced TNBC

December 10th 2025

Sara Tolaney, MD, MPH, discusses the clinical implications of sacituzumab govitecan in the first-line treatment of advanced triple-negative breast cancer.

Dr Rimm on Conceptual Considerations Surrounding ADC Mechanisms in Breast Cancer

December 10th 2025

David Rimm, MD, PhD, discusses key conceptual considerations and discrepancies regarding the mechanisms of action of ADCs in breast cancer treatment.

Dr Vincent-Salomon on Persisting Gaps in Clinical Interpretation of Invasive Lobular Carcinoma

December 9th 2025

Anne Vincent-Salomon, PR, MD, PhD, HDR, highlights persistent gaps that continue to challenge reproducibility and clinical interpretation in the diagnostic classification of invasive lobular carcinoma.

Experts Highlight HR+ and TNBC Trials to Watch Ahead of SABCS 2025

December 8th 2025

Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

December 7th 2025

Decitabine/cedazuridine plus venetoclax produced a 91% response rate and 30-month median OS in high-risk MDS/CMML.

Teclistamab/Daratumumab Doublet Is Highly Effective and Tolerable for Elderly Patients With Transplant-Ineligible NDMM

December 7th 2025

The “all-antibody–based” doublet generated high VGPR or better rates and had a favorable safety profile in the front line for this patient population.

KRd Demonstrates Superior PFS vs VRd in Newly Diagnosed Myeloma

December 6th 2025

KRd improved PFS, deepened responses, and led to higher MRD negativity vs VRd in newly diagnosed multiple myeloma.

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

December 6th 2025

Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.

BGB-16673 Is Safe, Highly Active Regardless of Baseline Mutations or High-Risk Features in R/R CLL/SLL

December 6th 2025

In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.

Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies

December 5th 2025

Ruchi J. Desai, MD, discusses future research directions in MPN and other hematologic malignancies.

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

December 5th 2025

Arvin K. George, MD, discusses the mechanism of water vapor thermal therapy and the implications of VAPOR 2 findings in prostate cancer management.

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

December 5th 2025

Timothy D. Lyon, MD, discuss logistical and clinical challenges faced by patients with non–muscle-invasive bladder cancer who undergo intravesical therapy.

Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025

December 5th 2025

A look at the top multiple myeloma abstracts set to be presented at the 2025 ASH Annual Meeting.

Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer

December 5th 2025

Komal Jhaveri, MD, FACP, discusses the clinical implications of the FDA approval of imlunestrant for pretreated, ESR1-mutated advanced breast cancer.

FDA Approves Liso-Cel for Relapsed/Refractory Marginal Zone Lymphoma

December 4th 2025

The FDA approved liso-cel for relapsed/refractory MZL after 2 prior lines of therapy.